AVAMAB PHARMA

Avamab Pharma Inc. was founded in 2018 in Calgary, Canada. Our executive and scientific team brings together decades of experience in drug development and taking new therapies to market. Our mission is to develop gene therapies to safely and effectively treat life-threatening infections, including those that have become resistant to existing treatments. To this end, we use our gene therapy platform, AAV-mAb, to make and release proprietary, specific monoclonal antibodies (mAb) against healthcare-acquired and pandemic infections... Our product candidates may be used both to treat active infections and prophylactically, to prevent infections from occurring.

Also known as: Avamab Pharma Inc.